Recent Progress in Endothelial Progenitor Cell Culture Systems: Potential for Stroke Therapy.
Recent Progress in Endothelial Progenitor Cell Culture Systems: Potential for Stroke Therapy.
复制标题
DOI：
10.2176/nmc.ra.2016-0027
复制
发表时间：
2016-06-15
影响因子：
1.9
通讯作者：
Asahara T
中科院分区：
文献类型：
--
作者：
Takizawa S;Nagata E;Nakayama T;Masuda H;Asahara T
内皮祖细胞（Endothelial progenitor cells，EPCs）由于其分化为内皮细胞并分泌保护性细胞因子和生长因子的能力而参与内皮修复和血管生成。因此，从外周血中分离的EPCs用于治疗各种缺血性损伤的细胞疗法引起了相当大的兴趣。近年来，人们建立了一种质量和数量可控的培养系统，以获得富含具有明确的血管生成和抗炎表型的EPCs的单核细胞，越来越多的动物模型和临床试验证据支持EPCs移植有助于缺血器官的再生过程，并有效治疗缺血性脑损伤。在这里，我们简要介绍了内皮祖细胞的一般特性，我们回顾了最近的发展，在培养系统和应用的内皮祖细胞和内皮祖细胞富集的细胞群治疗缺血性中风。
Endothelial progenitor cells (EPCs) participate in endothelial repair and angiogenesis due to their abilities to differentiate into endothelial cells and to secrete protective cytokines and growth factors. Consequently, there is considerable interest in cell therapy with EPCs isolated from peripheral blood to treat various ischemic injuries. Quality and quantity-controlled culture systems to obtain mononuclear cells enriched in EPCs with well-defined angiogenic and anti-inflammatory phenotypes have recently been developed, and increasing evidence from animal models and clinical trials supports the idea that transplantation of EPCs contributes to the regenerative process in ischemic organs and is effective for the therapy of ischemic cerebral injury. Here, we briefly describe the general characteristics of EPCs, and we review recent developments in culture systems and applications of EPCs and EPC-enriched cell populations to treat ischemic stroke.